



EBOS ANNOUNCES SETTLEMENT OF \$1.1B SYMBION ACQUISITION AND AN OVERSUBSCRIBED RIGHTS OFFER

News release

5 July 2013

The Directors of EBOS Group Limited (“**EBOS**”) are pleased to advise the successful completion today of the NZ\$1.1bn acquisition of Zuellig Healthcare Holdings Australia Pty Ltd (“**Symbion**”). Settlement of the transaction follows the conclusion of its NZ\$149.1 million 7:20 pro-rata renounceable rights issue which closed on 1 July 2013 substantially oversubscribed.

EBOS Managing Director, Mark Waller said: “The settlement of this acquisition concludes the successful completion of EBOS’ largest acquisition to date. This acquisition transforms EBOS into the largest diversified Australasian marketer, wholesaler and distributor of healthcare, medical and pharmaceutical products by revenue and a leading Australasian animal care products marketer, wholesaler and distributor.”

“The settlement marks the beginning of an exciting phase in EBOS’s evolution with management and board focus moving to capitalising on the opportunities a combination of these two leading businesses provides to generate long term value for our shareholders.”

“Whilst combined revenue is initially expected to be \$6 billion, looking forward, the increased scale and complementary nature of both businesses can be expected to open up additional revenue opportunities and operational efficiencies.”

In relation to the capital raising Mr Waller noted: “The very strong participation rate by existing shareholders under the entitlement offer, together with the substantial level of oversubscriptions received of approximately NZ\$60 million, were very pleasing and another strong endorsement of the transaction.”

For the purposes of the NZSX Listing Rules, EBOS advises the following:

- Subscriptions received under entitlements: 22,154,203 ordinary shares totalling NZ\$144.0 million, representing a take-up of entitlements of 97%;
- Under subscription for entitlements: 786,983 ordinary shares totalling NZ\$5.1 million, representing a shortfall in take-up of entitlements of 3%;
- Applications for additional shares under the oversubscription facility: 9,266,223 ordinary shares totalling NZ\$60.2 million;
- The rights issue was oversubscribed by 37% taking into account aggregate applications received (inclusive of applications for additional shares received under the oversubscription facility).

EBOS will allocate all shortfall shares to applicants for additional shares in accordance with the terms of the oversubscription facility. The new shares are expected to be issued on 5 July 2013, with shareholder statements to be dispatched shortly thereafter.

ENDS

Mark Waller
Managing Director/CEO
EBOS Group Ltd

DDI: (03) 339-5061
Mobile: 021-368746

For media inquiries:

Geoff Senescall
Senescall Akers Limited

Mobile: 021- 481234